Asset Advisors Investment Management LLC Has $304,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Asset Advisors Investment Management LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 27.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,502 shares of the biopharmaceutical company’s stock after selling 4,060 shares during the quarter. Asset Advisors Investment Management LLC’s holdings in Pfizer were worth $304,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. AlphaMark Advisors LLC increased its stake in shares of Pfizer by 61.7% in the second quarter. AlphaMark Advisors LLC now owns 1,703 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 650 shares during the last quarter. Silver Lake Advisory LLC acquired a new position in Pfizer in the 2nd quarter worth about $208,000. Blue Trust Inc. raised its stake in shares of Pfizer by 11.3% during the 2nd quarter. Blue Trust Inc. now owns 50,457 shares of the biopharmaceutical company’s stock worth $1,400,000 after purchasing an additional 5,136 shares in the last quarter. Stanley Laman Group Ltd. increased its holdings in Pfizer by 4.0% in the second quarter. Stanley Laman Group Ltd. now owns 52,430 shares of the biopharmaceutical company’s stock worth $1,467,000 after buying an additional 2,000 shares during the last quarter. Finally, Rovin Capital UT ADV raised its position in Pfizer by 18.6% during the second quarter. Rovin Capital UT ADV now owns 23,322 shares of the biopharmaceutical company’s stock valued at $653,000 after acquiring an additional 3,652 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on PFE shares. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Citigroup assumed coverage on Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective on the stock. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Bank of America reiterated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday. Finally, Guggenheim lowered their price target on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.43.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

PFE opened at $25.37 on Friday. The stock’s 50 day simple moving average is $27.23 and its 200-day simple moving average is $28.29. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $143.77 billion, a PE ratio of 34.28, a P/E/G ratio of 0.63 and a beta of 0.65. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.17) EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.78%. Pfizer’s payout ratio is currently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.